Phase Ib Study of PDR001 in Combination With Regorafenib in Adult Patients With Previously Treated Metastatic Microsatellite Stable (MSS) Colorectal Cancer
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 27 Dec 2018
At a glance
- Drugs Spartalizumab (Primary) ; Regorafenib
- Indications Adenocarcinoma; Colorectal cancer
- Focus Adverse reactions
- Sponsors Novartis Pharmaceuticals
- 14 Dec 2018 Planned End Date changed from 28 Feb 2019 to 5 Jun 2019.
- 14 Dec 2018 Planned primary completion date changed from 28 Feb 2019 to 5 Jun 2019.
- 14 Dec 2018 Status changed from recruiting to active, no longer recruiting.